

DAFTAR PUSTAKA

- Abraldes, J.G., Villanueva, C., Aracil, C., Turnes, J., Hernandez-Guerra, M., Rodriguez, M., *et al.* 2016. Addition simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increase survival in patients with cirrhosis. *Gastroenterol.* 150:1160–70.
- Abraldes, J.G., Albillos, A., Banares, R., Turnes, J., Gonzales, R., Garcia-Pagan, J.C., *et al.* 2009. Simvastatin lower portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. *Gastroenterol.* 136:1651-58.
- Adam, J.M.F., 2014. Dislipidemia. In: A. W. Sudoyo, B. Setiyohadi, I. Alwi, *et al.* (eds) *Buku Ajar Ilmu Penyakit Dalam*, pp:1978-83. edisi VI Jilid III. Interna Publishing, Jakarta.
- Andrikoula, M., Avades, T., 2006. Hypolipidemia is not always indicating liver dysfunction: a review primary and secondary high density lipoprotein and low density lipoprotein deficiencies [abstract]. *Minerva Med.* 97(6): 487-94.
- Bader, T., Korba, B., 2010. Simvastatin potentiates the anti-hepatitis B virus activity of FDA-approved nucleoside analogue inhibitors in vitro. *Antiviral Res.* 86(3):241-45.
- Bassani, L., Fernandes, S.A., Raimundo F.V., Harter, D.L., Gonzales, M.C., Marroni, C.A., 2012. Lipid profile of cirrhotic patients and its association with prognostic scores : a cross sectional study. *Arq Gastroenterol.* 52(3): 210-15.
- Bataller, R., Brenner, D.A., 2005. Liver Fibrosis. *J. of Clin. Invest.* 115(2):209-18.
- Bays, H., Cohen, D.E., Chalasani, N., Harrison, S.A., 2014. An assessment by the Statin Liver Safety Task Force: 2014 update. *J Clin Lipid.* 8: 47–57.
- Bissell, D.M., 1999. Sex and hepatic fibrosis. *Hepatology.* 29(3): 988-989.
- Bonis, P.A.L., Friedman, S.L., Kaplan, M.M., 2000. Is liver fibrosis reversible? *N Engl J Med*, 344: 452– 454.
- Butt, A.A., Yang, P., Bonilla, H., Abou-Samra, A-B., Shaikh, O.S., Simon, T.G., *et al.*, 2015. Effect of addition of statins to antiviral therapy in HCV infected persons: results from ERCHIVES. **doi:10.1002/hep.27835.**
- Calderon, M.R., Cubeddu, L.X., Goldber, R.B., Schiff, E.R., 2010. Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma. *Mayo Clin Proc.* 85(4):349-56.
- Campbell-McBride, N., 2008. Cholesterol: Friend or foe?. Available from: URL: www.westonprice.org/know-your-fats/cholesterol-friend-or-foe/.
- Canbay, A., Friedman, S., Gores, G.J., 2004. Apoptosis: the nexus of liver injury and fibrosis. *Hepatology.* 39: 273-8.
- Canbay, A., Higuchi, H., Bronk, S.F., Taniai, M., Sebo, T.J., Gores, G.J., 2002. Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. *Gastroenterology.* 123: 1323-30.

- Chrostek, L., Supronowicz, L., Panasiuk, A., Cylwik, B., Gruszevska, E., Flisiak, R., 2014. The effect of the severity of liver cirrhosis on the level of lipids and lipoprotein. *Clin Exp Med.* 14: 417–21.
- Cohen-Naftaly, M. and Friedman, S.L., 2011. Current status of novel antifibrotic therapies in patients with chronic liver disease. *Ther Adv Gastroenterol.* 4(6): 391-417.
- Criqui, M.H., 1994. Very low cholesterol and cholesterol lowering. A statement for healthcare professionals from the American Heart Association Task Force on cholesterol issues. *Circulation.* 90:2591.
- Dale, K.M., White, C.M., Henyan, N.N., 2007. Impact of statin dosing intensity on transaminase and creatinin kinase. In: Database of Abstract of Reviews of Effects (DARE).
- Dancygier, H., 2010. Liver Cirrhosis in Clinical Hepatology. Principles and Practice of Hepatobiliary Diseases. Volume 2. Springer-Verlag, Berlin.
- Elmehdawi, R.R., 2008. Hypolipidemia: a word caution. *Libyan J of Med.* 3(2): 84-90.
- Flores, P.P., Soldan, M., Rezend, G.F., 2015. Cirrhotic portal hypertenson : new insight in an old syndrome. *Revista Saude e Pesquisa.* 8(2): 389-97.
- Foucher, J., Chanteloup, E., Vergniol, J., Caste´ra, L., Le Bail, B., Adhoute, X., *et al.*, 2006. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. *Gut.* 55: 403–8.
- Franchis, R., 2005. *Evolving concensus In Portal Hypertension.* Report Of The Baveno IV Consensus Workshop on Methodology Of diagnosis and Therapy In Portal Hypertension. *J of Hepatol.* 43:167-76.
- Freeman, M., Kuiken, L., Ragland, J.B., Sabesin, S.M., 1977. Hepatic triglyceride lipase deficiency in liver disease. *Lipids.* 12(5): 443–5.
- Friedman, S.L., 2008. Mechanisms of hepatic fibrogenesis. *Gastroenterol.* 134: 1655-69.
- Friedmann, S., 2003. Liver Fibrosis-from bench to bedside. *J Of Hepatol.* 38:38-53.
- Ghadir, M.R., Riahin, A.A., Havaspour, A., Nooranipour, M., Habibinejad, A.A., 2010. The Relationship between Lipid Profile and Severity of Liver Damage in Cirrhotic Patients. *Hepat Mon.* 10:285 - 88.
- Gigante, A., Giraldi, G.D.L., Amoroso, D., Barbano, B., Dorelli, B., Mario, F.D., 2013. Statin in chronic liver disease.2(2).
- Goodman, L.S. and Gilman, A., 2008. The Pharmacological Basis Of Therapeutics. 11th ed. McGraw-Hill Companies, United States Of America.
- Guyton, A.C. and Hall, J., 2007. Buku Ajar Fisiologi Kedokteran. ed 9. Penerbit Buku Kedokteran EGC, Jakarta.
- Iglesias, A., Arranz, M., Alvarez, J.J., Perales, J., Villar, J., Herrera, E., *et al.* 1996. Cholesteryl ester transfer activity in liver disease and cholestasis, and its relation with fatty acid composition of lipoprotein lipids. *Clin Chimica Act.* 248:157–74.

- Imamura, M., Ogawa, T., Sasaguri, Y., Chayama, K., Ueno, H., 2005. Suppression of macrophage infiltration inhibits activation of hepatic stellat cells and liver fibrogenesis in rats. *Gastroenterology*. 128:138-46.
- Jang, E.S., Won, J., Jeong, S., 2011. The effect of antiviral therapy on serum cholesterol level in chronic hepatitis C. *Gut and Liver*. 5(3):356-62.
- Janicko, M., Drazilova S., Pella, D., Fedacko, J., Jarcuska, P., 2016. Pleiotropic effect of statins in the disease of the liver. *World J Gastroenterol*. 22(27): 6201-13.
- Jiang, M., Liu, F., Xiong, W.J., Zhong, L., Xu, W., Xu, F., et al., 2010. Combined MELD and blood lipid level in evaluating the prognosis of decompensated cirrhosis. *World J Gastroenterol*. 16(11):1397-401.
- Jung, Y.K. dan Yim, H.J., 2017. Reversal of liver cirrhosis: current evidence and exxpectations. *Korean J Intern Med*. 32:213-28.
- Katcher, H.I., Hill, A.M., Lanford, J.L., Yoo, J.S., Kris-Etherton, P.M., 2009. Lifestyle approach and dietary strategies to lower LDL-cholesterol and triglycerides and raise HDL-cholesterol. *Endocrin Metab Clin North Am*. 38(1):45-78.
- Kavalipati, N., Shah, J., Ramakrishan, A., Vasnawala, H., 2015. Pleiotropic effect of statins. *Indian J of Endocrin and Metabol*. 19(5): 554–62.
- Kim, H., Kisseleva, T., Brenner, D.A., 2015. Aging and liver disease. *Curr Opin Gastroenterol*. 31(3): 184–191.
- King, M.W., 2016. Major roles of biological lipids. Available from: URL: themedicalbiochemistrypage.org/lipids.php.
- Kingsbury, K.J. and Bondy, G., 2017. Understanding the essentials of blood lipid metabolism. Available from: URL: www.medscape.com/viewarticle/451762_3
- Knopp, R., 1999. Drug treatment of lipid disorders. *N Engl J Of Med*. 341(7):498-511.
- Kumar, S., Grace, N.D., Qamar, A.A., 2014. Statin Use in Patients with Cirrhosis: A Retrospective Cohort Study. *Dig Dis Sci*. 59:1958–65.
- Kusumobroto, H.O., 2007. Sirosis Hati. In: Sulaiman, A., Akbar, H.N., Nurul, A., Lesmana, L.A., Noer, M.S. (Ed.) Buku Ajar Ilmu Penyakit Hati, p335-45. Jaya Abadi, Jakarta.
- Kwan, B.C.H., Kronenberg, F., Beddhu, S., Cheung, A.K., 2007. Lipoprotein metabolism and lipid management in chronic kidney disease. *J Am Soc Nephrol*. 18:1246–61.
- Li, X., Gao, Y., Xu, h., Hou, J., Gao, P., 2017. Diabetes mellitus is significant risk factor for the development of liver cirrhosis in chronic hepatitis C. *Scientific Report*. 7:9087.
- Liao, J.K., 2002. Isoprenoids as mediators of the biological effects of statin. *J Clin Inves*. 110:285–8.
- Lingappa, V.R., 1997. Liver disease. In : Mcphe, S.J, Lingappa, V.R., Ganong, W.F., Lange, J.D. (Ed) Pathophysiology of diasease: an introduction of clinical medicine. 2nd edition. Appleton and Lange, Connecticut.
- Lochs, H., Plauth, M., 1999. Liver cirrhosis: rationale and modalities for nutritional support--the European Society of Parenteral and Enteral

- Nutrition consensus and beyond. *Curr Opin Clin Nutr Metab Care.* 4:345-49.
- Loria, P., Marchesini, G., Nascimbeni, F., Ballestri, S., Maurantano, M., Carubbi, F., *et al.*, 2014. Cardiovascular risk lipidemic phenotype and steatosis: a comparative analysis of cirrhotic and non cirrhotic liver disease due to vary etiology. *Atherosclerosis.* 232,:99–109.
- Mandal, A., 2012. Cholesterol Physiology. Available from: URL: www.news-medical.net/health/cholesterol-physiology.aspx.
- Mandal, S.K., *et al.*, 2013. A study on lipid profiles in chronic liver diseases. *Nat J of Med Res.* 3(1):70–2.
- Marinis, E., Martini, C., Trentalance, A., Pallottini, V., 2008. Sex differences in hepatic regulation of cholesterol homeostasis. *J of Endocrin.* 198:635-43.
- Maron, D.J., Fazio, S., Linton, M.F., 2000. Current perspectives on statins. *Circulation.* 101:207–13.
- Mason, J.C., 2003. Statins and their role in vascular protection. *Clin Science.* 105:251–66.
- Mehboob, F., Ranjha, F.A., Masud, S., 2007. Change in serum lipid profile among patients suffering from chronic liver disease. *Annals.* 13(3):209–11.
- Mombelli, g., Bosisio, R., Calabresi, L., Magni, P., Pavanello, C., Pazzucconi, F., *et al.*, 2015. Gender related lipid and/or lipoprotein responses to statins in subjects in primary and secondary prevention. *J of Clin Lipidol.* 9:226-33.
- Moutzouri, E., Elisaf, M., Liberopoulos, E.N., 2011. Hypocholesterolemia. *Cur Vasc Pharmacol.* 9:200–12.
- Nangliya, V.L., Sharma, A., Sunder, S, Yadav, D., Nijhawan, S., Mishra, S., 2015. Evaluation of lipid profile in patients with liver cirrhosis and their association with severity of the disease. *Int J of Recent in Sci and Tech.* 16(1):79–82.
- Naylor, P., Verkhovsky, E., Devara, A., Benjaram, S., Ehrinpreis, M., Mutchnick, M., 2018. Statin use is associated with reduction in fibrosis and cirrhosis in a predominantly african american urban population with hepatitis C. *Ann of Digest and Liv Dis.* 1(2).
- Nelson, R.H., 2013. Hyperlipidemia as a risk factor for cardiovascular disease. *Prim. Care.* 40(1):195-211.
- Nurdjanah S., 2009. Sirosis Hati. In: A. W. Sudoyo, B. Setiyohadi, I. Alwi, *et al.* (eds) *Buku Ajar Ilmu Penyakit Dalam*, p668-73. edisi V Jilid I. Interna Publishing, Jakarta.
- Nurdjanah S., 2014. Sirosis Hati. In: A. W. Sudoyo, B. Setiyohadi, I. Alwi, *et al.* (eds) *Buku Ajar Ilmu Penyakit Dalam*, p1978-83. edisi VI Jilid II. Interna Publishing, Jakarta.
- Oztas, Y., 2016. Hypocholesterolemia: a neglected laboratory finding. *Acta Med.* 5:9-12.
- Park, OY., Kim, S.H., Ahn, Y.K., Yun, N.S., Kim, J.H., Sim, D.S., *et al.* 2008. Statin reduce C-reactive protein and interleukin-6 in normocholesterolemic patients with acute coronary syndrome. *Chonnam Med J.* 44(1):13–16.

- Park, J.G., Tak, W.Y., Park, S.Y., Kweon, Y.O., Jang, S.Y., Lee, Y.R., *et al.*, 2017. Effects of branched-chain amino acids (BCAAs) on the progression of advanced liver disease. *Medicine*. 96:24.
- Pederson, T.R., Tobert, J.A., 2004. Simvastatin : a review. *Expert Opin Pharmacother*. 5(12):2583–96.
- Perret, B., Mabile., L., Martinez, L., Terce, F., Barbaras, R., Collet, X., 2002. Hepatic lipase: structure/function relationship, synthesis, and regulation. *J of Lipid Research*. 43:1163–69.
- Pollo-Flores, P., Soldan, M., Santos, U.C., Kunz, D.G., Mattos, D.E., da Silva, A.C., *et al.*, 2015. Three months of simvastatin therapy vs placebo for severe portal hypertension in cirrhosis: a randomized controlled trial. *Dig Liver Dis*.<http://dx.doi.org/10.1016/j.dld.2015.07.156>.
- Porth, C.M., 2005. Disease of hepatobiliary and exocrine pancreas. In : Pathophysiology concepts of altered health states. 7 th ed. Lippincott williams and Wilkins, Philadelphia.
- Price, S. and Wilson, L., 1994. Patofisiologi Konsep Klinis Proses-Proses Penyakit. EGC, Jakarta.
- Privitera, g., Spadaro, L., Marchisello, s., Fede, G., Purello, F., 2018. Abnormalitas of lipoprotein levels in liver cirrhosis: clinical relevance. *Digest Dis and Sci*. 63:16-26.
- Pugh, R.N., Murray-Lyon, I.M., Dawson, J.L., Pietroni, M.C., Williams, R., 1973. Transection of the oesophagus for bleeding oesophageal varices. *The British J of Surgery*. 60 (8):646–9.
- Ramasamy, I., 2014. Recent advances in physiological lipoprotein metabolism. *Clin Chem Lab Med*. 52(12):1695–727.
- Rambaldi, A. dan Gluud, C., 2005. Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis. *Cochrane Database Syst Rev*. 2:2148.
- Rockey, D.C., 2008. Curent and future anti-fibrotic therapies for chronic liver disease. *Clin Liver Dis*. 12(4):939-xi.
- Russo, W.M. and Jacobson, M., 2004. How to use statins in patients with chronic liver disease. *Cleveland Clin J of Med*.71:58-62.
- Sherlock, S. and Dooley, J.D., 2002. Hepatic Cirrhosis. In: S. Sherlock and J. D. Dooley (eds.) Diseases of the Liver and Biliary System. 11th ed.: Blackwell Science.
- Shirin.,H., Sharvit, E., Aeed, H., Gavish, D., Bruck, R., 2013. Atorvastatin and rosuvastatin do not prevent thioacetamide induced liver cirrhosis in rats. *World J Gastroenterol*. 9(2): 241-48.
- Shrirang, H., Deepali, V., Manjhusa, H., 2014. Serum lipid pattern in patients of liver cirrhosis. *IJAPB*. 1(3):9–12.
- Stancu, C., Sima, A., 2001. Statins: Mechanism Of Action And Effects. *J Cell Mol Med*. 4(5):378-87.
- Starr, SP., Raines, D., 2011. Cirrhosis: diagnosis, management, and prevention. *Am Fam Phycs*. 84(12):1353-59.
- Stee, M.F., de Graaf, A.A., Groen, A.K., 2018. Action of metformin and statins on lipid and glucose metabolism and possible benefit of combination therapi. *Cardiovasc Diabet*. 17:94.

- Suman, C., Kumar, B.R., Prabhakar, B., 2016. Lipid profile in assessing the severity of cirrhosis. *IAIM*. 3(6):113–23.
- Tandon, V., Bano, G., Khajuria, V., Parihar, A., Gupta, S., *et al.*, 2004. Pleiotropic effect of statins. *Indian J Pharmacol*.37(2):77-85.
- Thompson, T.E., 2017. Lipid biochemistry. Available from: URL: <http://www.britannica.com/science/lipid/functions-origins-and-recycling-of-apolipoproteins>.
- Tietge, U.J., Boker, k.H., Bahr, M.J., Weinber, S., Pichlmayr, R., Schmidt, H.H., *et al.*, 1998. Lipid parameters predicting liver function in patients with cirrhosis and after liver transplantation. *Hepatology*, 45(24), 2255-60.
- Tsochatzis, E.A., Bosch, J., Burroughs, A.K., 2014. Liver cirrhosis. *The Lancet*. 383:1749-61.
- Varghese, J.S., Krishnaprasad, K., Upadhuyay, R., Revathy, M.S., Jayanthi, V., 2007. Lipoprotein profile in cirrhosis of liver. *Eur J of Gastroenterol and Hep*.19:521–22.
- Vere, C.C., Streba, C.T., Streba, L., Rogoveanu, I., 2012. Lipid serum profile in patients with viral liver cirrhosis. *J Med Princ Pract*. 21:566–68.
- Wang, J. dan Hong, Z., 2014. Low plasma total cholesterol concentration: a sensitive evaluation marker in hospitalized patient with nutritional deficiency malnutrition. *J of Food and Nutri Research*. 2(9):551-55.
- Yang, Y-H., Chen, W-C., Tsan, Y-T., Chen, M-J., Shih, W-T., Tsai, Y-H., *et al.*, 2015. Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection. *J Hepatol*. 63(5):1111-17.
- Yoshiji, H., Noguchi, R., Ikenaka, Y., Kaji, K., Aihara, Y., Douhara, A., *et al.*, 2012. Combination of branched-chain amino acid and angiotensin-converting enzyme inhibitor improves liver fibrosis progression in patients with cirrhosis. *Molecular Med Reports*. 5:539-44.
- Zafra, C., Abraldes, J.G., Turnes, J., Berzigotti, A., Fernandez, M., Garca-pagan, J.C., *et al.*, 2004. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. *Gastroenterology*. 126(3):749-55.